Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
South Korea Deals Companies

Are Korean Biopharma Alliances Recovering After Gloomy Year?

Trend Toward Higher Upfronts

  • Analysis

Executive Summary

Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.

You may also be interested in...



BMS Spends $100m On Orum’s Antibody-Guided Protein Degrader

ORM-6151 combines two hot approaches in cancer R&D, but clinical trials have not yet started.

Daiichi In Massive $22bn Global Deal With Merck & Co For Three ADCs

The two firms will co-develop and co-commercialize three Daiichi ADCs globally outside Japan in a deal the Japanese firm said would allow “more aggressive development plans targeting broader patient populations.” 

Seagen And Nurix Hope To Pioneer A New Class Of Degrader-Antibody Conjugates

The two drug developers announced a collaboration to develop and commercialize multiple cancer programs. Nurix will receive $60m up front.

Table

View full table

Topics

Related Companies

Tags:
South Korea Deals Companies
Latest Headlines

China Seniors' Rising HIV Rates Pose Control Challenges

Seismic Rumbles Into Clinic With $121m For Novel Immunology Biologics

EyePoint Hits New Durability Milestone For Wet AMD Treatment

Roche Looks To Muscle Into Obesity Market With $2.7bn Carmot Buyout

See All
UsernamePublicRestriction

Register

SC149387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By